1. Introduction {#sec1-marinedrugs-17-00355}
===============

Part of the reasons for bacterial resistance to antibiotics are due to the formation of biofilm, composed of secreted polysaccharides, proteins, glycolipids and small molecules in the bacterial microenvironment. Recent development of antimicrobial agents with novel molecular mechanisms to control bacterial infectious diseases has drawn much attention \[[@B1-marinedrugs-17-00355]\]. The inhibition of bacterial biofilm formation by non-microbicidal mechanisms is an example of anti-pathogenic approaches \[[@B2-marinedrugs-17-00355],[@B3-marinedrugs-17-00355]\]. One nosocomial infectious bacteria, *Pseudomonas aeruginosa*, is responsible for various infections, particularly in immuno-compromised individuals \[[@B4-marinedrugs-17-00355]\], and it forms biofilms to make antibiotic treatments inefficient and therefore promotes acute infections, for example, at upper airway, skin, wound, urinary tract, enteric and lung \[[@B5-marinedrugs-17-00355]\]. *P. aeruginosa* PA14 is a clinically isolated and highly virulent strain representing the most common clonal group worldwide \[[@B6-marinedrugs-17-00355]\]. The PA14 genome showing a high degree of conservation compared to that of the *P. aeruginosa* strain PAO1 contains two specific pathogenicity islands. The PA14 islands carried several genes implicated in virulence that are absent in PAO1, including genes encoding effectors of the type III secretion system for secreting virulent factors \[[@B7-marinedrugs-17-00355],[@B8-marinedrugs-17-00355]\]. These characteristics make PA14 a threat to public health, but a good model for *P. aeruginosa* infection studies.

Biofilm development is associated with changes in bacteria phenotype and metabolic pathways \[[@B9-marinedrugs-17-00355]\]. During biofilm development, physiological changes of bacterial cells are regulated by a chemical signaling mechanism involving cell-to-cell communication, such as quorum-sensing (QS) signaling. The process of *P. aeruginosa* biofilm development is mainly regulated by three interconnected QS systems: Two use acyl-[l]{.smallcaps}-homoserine lactones (AHLs) and the third uses aquinolone \[[@B10-marinedrugs-17-00355]\]. In the AHL QS system, LasI-synthase generates *N*-(3-oxododecanoyl)-[l]{.smallcaps}-homoserine lactone \[[@B11-marinedrugs-17-00355]\] and RhlI synthase generates *N*-butyryl-[l]{.smallcaps}-homoserine lactone \[[@B12-marinedrugs-17-00355]\]. The former is a key factor in the maturation stage of the biofilm \[[@B13-marinedrugs-17-00355]\], and the latter is responsible for production of another biofilm regulator, di-rhamnolipid \[[@B14-marinedrugs-17-00355]\]. Numerous molecules with anti-QS property have been reported to inhibit biofilm formation of *P. aeruginosa* \[[@B15-marinedrugs-17-00355]\]. AHL analogues have inhibitory activities on biofilm formation in *P. aeruginosa* by down-regulating LasR-based QS system (LasR, a transcriptional regulator response for AHL). Some modified AHL analogues can also down-regulate pyocyanin, a virulence factor with elastase activity \[[@B16-marinedrugs-17-00355]\]. Certain enzymes are secreted by mammalian cells such as paraoxonases, which lactonase activity can degrade *P. aeruginosa* AHLs and further inhibit QS and biofilm formation. Most of these AHL pathway inhibitors efficiently work under 10 μM.

There already exist many different anti-biofilm agents from various resources. For example, cultured broth from certain marine cold adapted bacteria destabilized biofilm of *Pseudomonas aeruginosa* \[[@B17-marinedrugs-17-00355]\] and some essential oils from Mediterranean plants or selected exopolysaccharide from marine bacteria acts as anti-QS factors to inhibit biofilm formation of *Pseudomonas aeruginosa* \[[@B18-marinedrugs-17-00355],[@B19-marinedrugs-17-00355]\]. Although AHL pathway inhibitors already exist, they still cannot completely inhibit the biofilm produced by *P. aeruginosa* \[[@B15-marinedrugs-17-00355]\], indicating that biofilm development is not only controlled by the AHL pathway but also other pathways that might partially complement to develop biofilm. This hypothesis leads us to focus on factors that may directly regulate biofilm development. Di-rhamnolipid, as a glycolipid secreted by *P. aeruginosa*, has been implicated in each of the following phases of biofilm development: (i) Forming microcolonies \[[@B20-marinedrugs-17-00355]\], (ii) regulating both cell-to-cell and cell-to-surface interactions \[[@B21-marinedrugs-17-00355]\], (iii) creating and maintaining fluid channels for water and oxygen flow around the base of the biofilm \[[@B21-marinedrugs-17-00355]\] and (iv) facilitating 3-D mushroom-shaped structure formation \[[@B22-marinedrugs-17-00355]\]. Accordingly, di-rhamnolipid seems to be a regulator that might directly interact with biofilms. The influence of di-rhamnolipid to biofilm development was observed, but the interaction of di-rhamnolipid with other QS factors remains unclear. To develop anti-biofilm reagents directly targeting di-rhamnolipid might be a novel anti-biofilm approach.

Rhamnose binding proteins (RBPs) are mainly isolated from eggs, ovary cells of fish and invertebrates with [l]{.smallcaps}-rhamnose (Rha) or [d]{.smallcaps}-galactose binding specificities \[[@B23-marinedrugs-17-00355],[@B24-marinedrugs-17-00355]\]. RBPs are typically located in immune-related tissues or cells \[[@B25-marinedrugs-17-00355]\], suggesting that RBPs may be relevant to self-defense mechanisms. RBPs may interact and agglutinate Gram-negative and Gram-positive bacteria by recognizing lipopolysaccharide (LPS) and lipoteichoic acid (LTA), respectively \[[@B26-marinedrugs-17-00355]\]. RBPs can recognize some *O*-antigens and bind to glycolipids and glycoproteins of fish pathogens \[[@B27-marinedrugs-17-00355]\]. The RBP receptor is expressed on peritoneal macrophages of fish after an inflammatory stimulation \[[@B28-marinedrugs-17-00355]\]. The tissue specificity of expression and ability to interact with bacteria indicates that RBPs are naturally related to the innate immune system in animals as a pathogen recognition element.

An RBP possessing specific binding of [l]{.smallcaps}-rhamnose was discovered from horseshoe crab plasma and recently engineered for expression in the *Escherichia coli* system \[[@B29-marinedrugs-17-00355]\]. This recombinant horseshoe crab plasma lectin (rHPL) possesses a very low sequence identity with known RBPs and does not have conserved domains. Interestingly, rHPL binds to bacteria or pathogen-associated molecular patterns (PAMPs) by recognizing rhamnose moieties and inhibits the growth of *P. aeruginosa* \[[@B29-marinedrugs-17-00355]\]. Unlike other RBLs, rHPL only binds to [l]{.smallcaps}-rhamnose and rhamnobiose but not to galactose or mannose \[[@B30-marinedrugs-17-00355]\]. This high substrate specificity makes rHPL a prospective candidate to bind rhamnose-containing components in biofilm of *P. aeruginosa* and examine the biological functions of these bindings.

2. Results {#sec2-marinedrugs-17-00355}
==========

2.1. rHPL~OE~ Was Expressed in E. coli and Purified by Affinity Chromatography {#sec2dot1-marinedrugs-17-00355}
------------------------------------------------------------------------------

rHPL was successfully expressed in *E. coli* in 2014. The yield of rHPL purified using a nickel-affinity column was \~8 mg/L, and the purity was 93% \[[@B29-marinedrugs-17-00355]\]. To improve the productivity and solubility of rHPL, the codon usage of synthetic *hpl* (*hploe*) was optimized for *E. coli*, and recombinant HPL~OE~ was co-expressed with chaperones. The expression product, rHPL~OE~, was purified by fast protein liquid chromatography (FPLC) equipped with a HisTrap™ affinity column following purification scheme in supplementary data showed in [Table S1](#app1-marinedrugs-17-00355){ref-type="app"}. rHPL~DM~, representing rHPL with two artificial mutations Y88A and F145A, which showed no binding activities to a bacterial cell- ([Figure S1A](#app1-marinedrugs-17-00355){ref-type="app"}) or pathogen-associated molecular pattern (PAMP; [Figure S1B](#app1-marinedrugs-17-00355){ref-type="app"}), was applied as a negative control in this study. [Figure S2](#app1-marinedrugs-17-00355){ref-type="app"} illustrated the purification chromatogram and SDS polyacrylamide gel electrophoresis analysis data. The purified rHPL~OE~ was desalted and concentrated using an Amicon protein concentrator (10 kDa cut-off) and subjected to further analysis. [Figure S3](#app1-marinedrugs-17-00355){ref-type="app"} showed the secondary structure of rHPL~OE~ determined by circular dichroism (CD) spectroscopy in comparison to those of rHPL and rHPL~DM~, indicating that both rHPL~OE~ and rHPL~DM~ possessed similar structures to rHPL \[[@B29-marinedrugs-17-00355]\]. A yield of 11.33 mg/L rHPL~OE~ with a comparable purity. The yield of rHPL~OE~ was 1.4-fold higher than that of rHPL, suggesting that the chaperone improved the solubility and stability of rHPL in the *E. coli* system.

2.2. rHPL~OE~ Bound to Cell-Free Biofilm Matrix from P. aeruginosa PA14 via Recognizing Rhamnose {#sec2dot2-marinedrugs-17-00355}
------------------------------------------------------------------------------------------------

Our hypothesis is that rHPL~OE~ might bind to rhamnose-containing components in the biofilm and further interrupt bacterial biofilm development. First, binding capacity of rHPL~OE~ to the cell-free biofilm matrix from *P. aeruginosa* PA14 was tested. Here, a mature *P. aeruginosa* PA14 biofilm was extracted using a NaCl solution to give a cell-free biofilm matrix. In the extracted PA14 biofilm, the total protein was 0.19 mg/mL and polysaccharide, 0.32 mg/mL. Di-rhamnolipid, an important QS-factor and putative binding target of rHPL~OE~, was extracted using chloroform, and was 0.66 μg/mL by methylene blue method. The interaction between rHPL~OE~ and the cell-free biofilm matrix was measured by ELISA, and the inhibitory effect of monosaccharides and alginate on rHPL~OE~-biofilm interaction was determined using competitive ELISA. rHPL~OE~ at a final concentration of 0.1 μM was mixed with [l]{.smallcaps}-rhamnose and loaded into microplate wells coated separately with extracted *P. aeruginosa* PA14 biofilm. rHPL~OE~ mixed with buffer only was used as a positive control. rHPL~DM~ without rhamnose binding activity served as a negative control. As shown in [Figure 1](#marinedrugs-17-00355-f001){ref-type="fig"}, addition of 25, 50, and 100 mM of [l]{.smallcaps}-rhamnose effectively reduced binding of rHPL~OE~ to the extracted biofilm, in comparison with the positive control. The inhibitory constant (*K~i~*) of [l]{.smallcaps}-rhamnose to rHPL~OE~ interaction with the biofilm of *P. aeruginosa* PA14 was 98 mM. The addition of 100 Mm of [d]{.smallcaps}-mannose, [d]{.smallcaps}-glucose, [d]{.smallcaps}-fructose, [d]{.smallcaps}-galactose and alginate could not reduce the binding between rHPL~OE~ and the extracted biofilm. These results indicated that rHPL~OE~ specifically bound to rhamnose containing components in *P. aeruginosa* PA14 biofilm.

2.3. Synthetic Rhamnobiosides and a Pentasaccharide Inhibited rHPL~OE~-Biofilm Interaction {#sec2dot3-marinedrugs-17-00355}
------------------------------------------------------------------------------------------

To confirm that binding of rHPL~OE~ to the *P. aeruginosa* PA14 biofilm was via molecular recognition of rhamnose moiety, synthetic rhamno-oligosaccharides ([Figure 2](#marinedrugs-17-00355-f002){ref-type="fig"}A,B) were used as competitors in a competitive ELISA. The chemical synthesis of phenylthio-rhamnobiosides and the Psl-pentasaccharide will be published elsewhere. The characterization of the new oligosaccharides used in this study is given in the [Supplementary Information (Figures S4--S6)](#app1-marinedrugs-17-00355){ref-type="app"}.

[Figure 2](#marinedrugs-17-00355-f002){ref-type="fig"} indicated that all synthetic compounds competed with the rHPL~OE~-biofilm interaction. The disaccharides are better inhibitor than monosaccharides, and (1-3)-linked rhamnosides were better than its (1-2)-linked counterparts. Psl-pentasaccharide showed the strongest competition presumably due to longer glycan chain length. The competitive effects of rhamnobiosides were stronger than those of rhamnobioses, indicating either a fixed anomeric configuration or hydrophobicity of aglycones slightly favors binding.

2.4. rHPL~OE~ Bound to Di-Rhamnolipid via Recognizing Rhamnose Portion {#sec2dot4-marinedrugs-17-00355}
----------------------------------------------------------------------

After confirming the binding activity of rHPL~OE~ to synthetic rhamnobiosides, direct binding activity of rHPL~OE~ to di-rhamnolipid from *P. aeruginosa* PA14 biofilm was measured by ELISA. Further competitive ELISA indicated that rHPL~OE~ binding to di-rhamnolipid could be competed more effectively by [l]{.smallcaps}-rhamnose compared to other monosaccharides ([Figure 3](#marinedrugs-17-00355-f003){ref-type="fig"}).

2.5. rHPL~OE~ Inhibited Biofilm Formation and Dispersed the Preformed Biofilm of P. aeruginosa PA14 {#sec2dot5-marinedrugs-17-00355}
---------------------------------------------------------------------------------------------------

This experiment was conducted in M63 broth, a minimal low-osmolarity medium to slow down the growth rate of bacteria and mimic nutrient-depleted conditions for biofilm growth \[[@B31-marinedrugs-17-00355]\]. rHPL~DM~ was applied as a negative control. As shown in [Figure 4](#marinedrugs-17-00355-f004){ref-type="fig"}A, 0.31 µM and higher concentrations up to 5 µM of rHPL~OE~ significantly inhibited the biofilm formation of *P. aeruginosa* PA14. Treatment with 0.31, 0.63, 1.25, 2.5 and 5 µM rHPL~OE~ significantly reduced biofilm formation to 49%, 51%, 39%, 18% and 13%, respectively. As expected, rHPL~DM~ did not inhibit biofilm formation. rHPL~OE~ was also evaluated for its biofilm dispersion activity with preformed biofilm. The mature biofilm of *P. aeruginosa* PA14 was dispersed by 16% and 24% upon treatment with 2.5 and 5 µM rHPL~OE~ for 24 h, respectively ([Figure 4](#marinedrugs-17-00355-f004){ref-type="fig"}B). However, rHPL~DM~ did not disperse the mature biofilm. These results indicated that rHPL~OE~ inhibited biofilm formation and dispersed the mature biofilm of *P. aeruginosa* PA14 and that both activities perhaps are correlated with the rhamnose binding activity.

2.6. rHPLOE Inhibited Swarming Activity and Decreased Secreted Rhamnolipids of P. aeruginosa PA14 {#sec2dot6-marinedrugs-17-00355}
-------------------------------------------------------------------------------------------------

Swarming motility is positively correlated with the amount of extracellular rhamnolipids, leading to rapid bacterial translocation that promotes efficient colonization of bacterial cells on a surface \[[@B32-marinedrugs-17-00355]\]. Under optimal growth conditions, *P. aeruginosa* cell population would spread along a solid surface and cover a large area. If swarming were inhibited, the bacterial cell population would gather together to form a colony. The swarming area of *P. aeruginosa* PA14 was significantly reduced upon treatment with rHPL~OE~ but not rHPL~DM~ ([Figure S7A](#app1-marinedrugs-17-00355){ref-type="app"}). The swarming area of PA14 was reduced by 33%, 43%, 48% and 46%, respectively, upon treatment with 0.63, 1.25, 2.5 and 5 µM rHPL~OE~ for 72 h ([Figure S7B](#app1-marinedrugs-17-00355){ref-type="app"}). [Figure 5](#marinedrugs-17-00355-f005){ref-type="fig"} showed that the extracellular rhamnolipid levels of PA14 (11.7 ± 0.4 μg/mL in the control treated with buffer) reduced by 44%, 50%, 54%, 64% and 59% upon treatment with 0.31, 0.63, 1.25, 2.5 and 5 µM rHPL~OE~, respectively. However, the 5 µM rHPL~DM~ treatment did not affect the extracellular rhamnolipid levels of PA14. This result was consistent with the swarming assay, indicating that the binding of rHPL~OE~ to biofilm inhibited PA14 swarming activity by down-regulating the levels of extracellular di-rhamnolipid.

2.7. rHPL~OE~ Attenuated QS-Associated Factors {#sec2dot7-marinedrugs-17-00355}
----------------------------------------------

The development of biofilms appears to be regulated by the QS system. Most reagents that attenuate biofilm development work through inhibiting production of QS-factors or disrupting function of QS-factors by direct binding to QS-factors \[[@B33-marinedrugs-17-00355],[@B34-marinedrugs-17-00355],[@B35-marinedrugs-17-00355]\]. Among these agents, pyoverdine and pyocyanin are unique toxic molecules related to the virulence of *P. aeruginosa* PA14. To understand the attenuation mechanism of *P. aeruginosa* biofilm by rHPL~OE~, the effect of rHPL~OE~ on QS-mediated azocasein-degrading protease activity and the secretion of two virulent factors, pyoverdine and pyocyanin were evaluated. Bacterial extracellular proteases degrade proteins in host cells (infected tissue), thereby facilitating bacterial invasion and growth \[[@B36-marinedrugs-17-00355]\]. Interestingly, bacterial protease secretion by *P. aeruginosa* PA14 was down-regulated by rHPL~OE~ treatment ([Figure S8A](#app1-marinedrugs-17-00355){ref-type="app"}). The azocasein-degrading assay showed that 1.25 and 2.5 µM rHPL~OE~ respectively decreased 16% and 12% of total proteolytic activities. Treatment with 0.31, 0.63, 1.25 and 2.5 µM rHPL~OE~ decreased the pyoverdine levels by 12%, 8%, 17% and 21%, respectively ([Figure S8B](#app1-marinedrugs-17-00355){ref-type="app"}). Treatment with the same concentrations of rHPL~OE~ decreased the pyocyanin levels by 41%, 56%, 45% and 40%, respectively ([Figure S8C](#app1-marinedrugs-17-00355){ref-type="app"}).

These results indicated that the binding of rHPL~OE~ to the biofilm down-regulated the protease activities and QS-factors ([Table 1](#marinedrugs-17-00355-t001){ref-type="table"}). Consistent with previous observations, 2.5 µM rHPL~DM~ did not show an inhibitory effect. Relatively weak inhibition of rHPL~OE~ on protease activity and pyoverdine expression indicated that these effects might be indirect effects. The effect of rHPL~OE~ on pyocyanin production was detectable but not concentration-dependent. A possible alternate reason for this may be that the inhibition effect of rHPL~OE~ on pyocyanin production was compensated by other regulatory pathways.

2.8. Combination Treatment with rHPL~OE~ Improved Efficacies of Antibiotics on P. aeruginosa with Preformed Biofilms {#sec2dot8-marinedrugs-17-00355}
--------------------------------------------------------------------------------------------------------------------

Since rHPL~OE~ exhibited dispersion of *P. aeruginosa* PA14 biofilm, we hypothesized that rHPL~OE~ might increase the activities of antibiotics against *P. aeruginosa* PA14 in mature biofilms. Total protein assay showed that the combination of rHPL~OE~ with either azithromycin (hydrophobic) or cephalexin (hydrophilic) significantly attenuated the total protein levels in the biofilm. The IC50 of azithromycin and cephalexin to *P. aeruginosa* PA14 with pre-formed biofilm was 27.3 ± 1.4 and 27.7 ± 0.9 μg/mL, respectively. In the presence of 25 μg/mL azithromycin, in combination with 0.31, 0.63, 1.25 and 2.5 µM rHPL~OE~ reduced the total protein in the biofilm by 19%, 21%, 39% and 43%, respectively, compared to the antibiotic-only control ([Figure 6](#marinedrugs-17-00355-f006){ref-type="fig"}).

In the presence of 25 μg/mL cephalexin, combination treatment with the same concentrations of rHPL~OE~ reduced the total protein in biofilms by 33%, 33%, 38% and 50%, respectively, compared to the antibiotic-only control ([Figure 6](#marinedrugs-17-00355-f006){ref-type="fig"}). This observation suggested that rHPL~OE~ might facilitate antibiotics to kill *P. aeruginosa* PA14 by partially interfering with biofilm regulation and thus destroying the structure of the mature biofilm.

2.9. rHPL~OE~ Inhibited Infection of P. aeruginosa in Mammalian Cells and Zebrafish Embryos {#sec2dot9-marinedrugs-17-00355}
-------------------------------------------------------------------------------------------

During *P. aeruginosa* infection, rhamnolipids and pyocyanin are the important virulence factors causing cytotoxicity. Since rHPL~OE~ inhibited rhamnolipid and pyocyanin production in *P. aeruginosa* PA14, we predicted that rHPL~OE~ could also reduce *P. aeruginosa* PA14 infection inhuman lung cells. To evaluate this hypothesis, cell death of human lung cell line A549 by *P. aeruginosa* PA14 infection in the presence of rHPL~OE~ was examined. As shown in [Figure 7](#marinedrugs-17-00355-f007){ref-type="fig"}, the PA14-infected A549 cell death was reduced by 14%, 21%, 57% and 73% in the presence of 0.31, 0.63, 1.25 and 2.5 µM rHPL~OE~, respectively.

Regarding the negative control, 2.5 µM BSA or 2.5 µM rHPL~DM~ did not influence A549 cell death. These assays clearly demonstrated that the mortality rate of A549 cells killed by *P. aeruginosa* PA14 decreased due to the presence of rHPL~OE~. Therefore, rHPL~OE~ attenuated *P. aeruginosa* PA14 infection in human lung A549 cells through direct interaction between rHPL~OE~ and rhamnose-containing bacterial compounds.

Zebrafish (*Danio rerio*) has become an important vertebrate animal model for many disease studies including pathogen infection \[[@B37-marinedrugs-17-00355]\] in recent years. Here fertilized eggs from zebrafish were used as an animal model to evaluate whether rHPL~OE~ attenuated *P. aeruginosa* PA14 infection in vivo. Zebrafish embryos showed normal development in the absence of *P. aeruginosa* PA14, while the development of most embryos was significantly delayed or even died at 48 h following infection with *P. aeruginosa* PA14 ([Figure 8](#marinedrugs-17-00355-f008){ref-type="fig"}).

However, when *P. aeruginosa* PA14 was pre-incubated with 5 μM rHPL~OE~, 82.2% of embryos developed normally as compared to control embryos showing a development rate of 90.9%. Zebrafish embryos treated with 2.5 μM rHPL~OE~ still developed slowly, but almost all of the embryos survived. These results indicated that rHPL~OE~ could protect zebrafish embryos from *P. aeruginosa* PA14 infection at concentrations higher than 2.5 μM.

3. Discussion {#sec3-marinedrugs-17-00355}
=============

To study the carbohydrate components of the biofilm, carbohydrate-binding proteins, such as plant lectins, have been widely applied. Previously many different neutral carbohydrates including *N*-acetyl-[d]{.smallcaps}-glucosamine, *N*-acetyl-[d]{.smallcaps}-galactosamine, [d]{.smallcaps}-glucose and [d]{.smallcaps}-mannose were identified in the exopolymeric matrix of the biofilm \[[@B38-marinedrugs-17-00355]\]. Lectins with various specificities show an interaction with the carbohydrate components of biofilms. For example, concanavalin A from *Canavalia ensiformis* seeds is specific for [d]{.smallcaps}-glucose and [d]{.smallcaps}-mannose \[[@B39-marinedrugs-17-00355]\], and lectin from *Triticum vulgaris* germs is specific for *N*-acetyl-[d]{.smallcaps}-glucosamine and sialic acid \[[@B40-marinedrugs-17-00355]\]. [l]{.smallcaps}-Rhamnose as a unique sugar in bacteria and plants is a common component of the cell wall and capsule of many pathogenic bacteria including Gram-negative *P. aeruginosa* \[[@B41-marinedrugs-17-00355]\], *Salmonella typhimurium* \[[@B42-marinedrugs-17-00355]\], *Vibrio cholera* \[[@B43-marinedrugs-17-00355],[@B44-marinedrugs-17-00355]\] as well as *Mycobacterium tuberculosis* \[[@B45-marinedrugs-17-00355]\]. *P*. *aeruginosa* produces at least three distinct exopolysaccharides that contribute to biofilm development and architecture: Alginate, Pel and Psl \[[@B46-marinedrugs-17-00355]\]. Alginate consists of only uronic acids, Pel is a glucose-rich polysaccharide and Psl consists of a repeating pentasaccharide containing [d]{.smallcaps}-mannose, [d]{.smallcaps}-glucose and [l]{.smallcaps}-rhamnose \[[@B47-marinedrugs-17-00355]\]. Psl serves as a primary structural scaffold for biofilm development. In addition, Psl is involved in early stages of biofilm formation and promoting cell-to-cell interactions \[[@B48-marinedrugs-17-00355],[@B49-marinedrugs-17-00355]\]. Another rhamnose-containing component in the biofilm was the QS-factor di-rhamnolipid. A mutant strain (*P. aeruginosa* PAO1C-*rhlAB*) that could not produce rhamnolipids lost its swarming activity, which agreed with our observation in rHPL~OE~-treated PA14 \[[@B50-marinedrugs-17-00355]\]. rHPL~OE~ bound to both Psl and di-rhamnolipid through targeting rhamnose moiety and synthetic rhamnobiosides-competitive ELISA showed that rHPL~OE~ preferred to bind with α(1-3)-rhamnobiose rather than α(1-2)-rhamnobiose. The linkage of the rhamnose of Psl was reported to be α(1-3) \[[@B47-marinedrugs-17-00355]\] while that of di-rhamnolipid was α(1-2) \[[@B51-marinedrugs-17-00355]\], perhaps favoring that rHPL~OE~ binding to rhamnose component in biofilm was governed by recognition of unique structure feature of rhamnosyl moiety. Although rHPL~OE~ binding to Psl still required more abundant glycan for detail characterization, rHPL~OE~ binding to di-rhamnolipid down-regulated the expression of di-rhamnolipid and QS-factors of *P. aeruginosa* and further inhibited biofilm formation.

The most important finding of this study was that the binding of rHPL~OE~ to the *P. aeruginosa* PA14 biofilm inhibited biofilm development and disrupted the mature biofilm. Our data clearly showed that rHPL~OE~ caused these bio-effects by interacting with components in the biofilm including structural polysaccharides or di-rhamnolipid, largely due to the down-regulation of QS-factors including di-rhamnolipid, pyocyanin, pyoverdine and extracellular proteases by interrupting the functions of di-rhamnolipid.

Based on the biofilm dispersion activity of rHPL~OE~, we proposed that rHPL~OE~ possessed synergistic effects with antibiotics on *P. aeruginosa*. Two antibiotics commonly applied for treating *P. aeruginosa* infections, azithromycin, a hydrophobic azalide that kills bacteria by decreasing protein production and cephalexin, a hydrophilic beta-lactam that kills bacteria by inhibiting cell wall synthesis, were used in this study in combination with rHPL~OE~. The results showed that rHPL~OE~ significantly improved the bactericidal activity of both antibiotics, strongly suggesting that rHPL~OE~ was useful as a biofilm dispersion reagent for deconstructing the biofilm and improving the activities of antibiotics.

Many studies reported that *P. aeruginosa* infection could be inhibited by down-regulating QS-factors. Importantly, these anti-QS reagents (allicin, triazolyldihydrofuranone and baicalin hydrate) are effective against multidrug-resistant *P. aeruginosa* \[[@B33-marinedrugs-17-00355],[@B34-marinedrugs-17-00355],[@B35-marinedrugs-17-00355]\]. Studies in the past decade revealed that these anti-QS reagents also inhibited many human infections caused by biofilm-producing bacteria \[[@B52-marinedrugs-17-00355],[@B53-marinedrugs-17-00355]\]. This fact is important for fighting human pathogenic bacteria, as biofilms are found to be involved in over 80% of microbial infections in humans \[[@B54-marinedrugs-17-00355]\]. Since rHPL~OE~ could reduce the levels of pyoverdine and pyocyanin, we speculate that rHPL~OE~ might also inhibit *P. aeruginosa* infection. It was found that rHPL~OE~ significantly reduced the cytotoxicity towards A549 cells and neutralized toxicity (leading to development retardation or death) of the zebrafish embryo caused by *P. aeruginosa* PA14.

4. Conclusions {#sec4-marinedrugs-17-00355}
==============

Binding and down-regulation of di-rhamnolipid has not attracted much attention so far. In this study, we optimized the production of rHPL in *E. coli* using chaperone co-expression. rHPL~OE~, a highly specific rhamnose binding protein, bound to not only bacterial cells and PAMPs \[[@B29-marinedrugs-17-00355]\] but also extracted cell-free biofilm from *P. aeruginosa*. In addition, such interaction inhibited biofilm formation and dispersed mature biofilm through down-regulating secretion of di-rhamnolipid in biofilm and further down-regulating other QS-factors including extracellular proteases, pyoverdine and pyocyanin. As a biofilm dispersion reagent, rHPL~OE~ increased the antibiotic activity against *P. aeruginosa* PA14 with pre-formed biofilm. Therefore, rHPL~OE~ promised to be an effective anti-biofilm agent for combination therapy. At cellular and animal levels, rHPL~OE~ inhibited the infection and toxicity of *P. aeruginosa* PA14 towards human lung epithelial cells and zebrafish embryos. These results indicated that rHPL~OE~ served as a novel anti-biofilm agent by targeting rhamnose-containing components in biofilm, which in turn linked glycan-recognition to novel anti-biofilm strategies against pathogenic bacteria.

5. Materials and Methods {#sec5-marinedrugs-17-00355}
========================

5.1. Bacteria Strains, Growth Medium and Plasmid {#sec5dot1-marinedrugs-17-00355}
------------------------------------------------

*Escherichia coli* TOP10F' (Invitrogen, Waltham, MA, USA) was used as a host for vector construction and DNA manipulation. *E. coli* BL21(DE3) (Invitrogen, Waltham, MA, USA) was used as a host for protein expression. *Pseudomonas aeruginosa* PA14 (serotype O19) was kindly provided by Dr. Hwan-You Chang (Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, Taiwan). The vector pET-23a (+) (Novagen, Burlington, MA, USA) with a T7 promoter was used for recombinant protein expression in *E. coli* cells and sequence analysis. Takara's Chaperone Plasmid Set (\#3340, TaKaRa, Shiga, Japan) was used for chaperone co-expression. All other buffers and reagents were of the highest commercial purity.

5.2. Expression and Purification of rHPL~OE~ {#sec5dot2-marinedrugs-17-00355}
--------------------------------------------

Chloramphenicol (≥98%, \#C0378), ampicillin (96%--102%, \#A9393), isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside (IPTG, ≥99%, \#I6758), Tris base (ACS reagent, ≥99.8%, \#252859), NaCl (ACS reagent, ≥99%, \#746398), imidazole (≥99%, \#I5513), HCl (\#320331) and phenylmethylsulfonyl fluoride (PMSF, ≥99%, \# 78830) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Luria-Bertani (LB, \#244610) was purchased from BD (Franklin lake, NJ, USA). rHPL~OE~ was the chaperone co-expressed product of the synthesized sequence (*hpl~OE~*) and the codon of *hpl~OE~* was optimized for *E. coli* expression. To generate a co-expression clone, pET23a-*hpl~OE~* was transformed into *E. coli* BL21(DE3) competent cells containing pG-KJE8 (\#3340, TaKaRa, Shiga, Japan), and transformants were selected by an LB plate with 20 μg/mL chloramphenicol and 50 μg/mL ampicillin. After induction with a final concentration of 0.1 mM IPTG at 16 °C for 16 h, cells were harvested by centrifugation (KUBOTA, Osaka, Japan), and the residues were suspended in equilibrium buffer (20 mM Tris-HCl, 200 mM NaCl and 5 mM imidazole, pH 7.4) supplemented with a protease inhibitor (1 mM PMSF) and disrupted by three passages through a cell homogenizer (Sonicator 3000, Misonix, Farmingdale, NY, USA) at 15,000 psi. The recombinant proteins were purified using a HisTrap™ HP immobilized metal ion affinity column (\#17524701, GE Healthcare, Little Chalfont, Buckinghamshire, UK) and ÄKTA start system (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Purified proteins were then concentrated and buffer-exchanged to the Tris buffer (20 mM Tris-HCl and 200 mM NaCl, pH 7.4) using a 15 kDa cut off Amicon Ultra centrifugal filter unit (\#UFC901096, Millipore, Burlington, MA, USA).

5.3. Biofilm Formation and Extraction {#sec5dot3-marinedrugs-17-00355}
-------------------------------------

Bacterial biofilm extraction was as described by Chibaet et al. \[[@B55-marinedrugs-17-00355]\]. *P. aeruginosa* PA14 grown on LB plates was inoculated in LB medium and incubated overnight at 37 °C with 250 rpm circular shaking. A portion of the overnight culture was 1000-fold diluted in 10 mL LB medium and incubated at 37 °C to an A600nm of 1. Bacterial cells with biofilm were harvested from incubated solution by centrifugation at 8000× *g* for 10 min at 25 °C (KUBOTA, Osaka, Japan). The harvested pellet was re-suspended with 1 mL of 1.5 M NaCl to extract a cell-free biofilm component. The suspensions were centrifuged at 5000× *g* for 10 min at 25 °C (KUBOTA, Osaka, Japan), and the supernatants containing the biofilm fraction were collected.

5.4. Polysaccharide Quantification in the Extracted Biofilm {#sec5dot4-marinedrugs-17-00355}
-----------------------------------------------------------

Absolute ethanol (≥99.8%, \#32221), phenol (\#P1037) and sulfuric acid (95%--98%, \#435589) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Polysaccharide in biofilm was measured as described by Tribedi and Sil \[[@B56-marinedrugs-17-00355]\]. Extracted biofilm solution was mixed with 2.2 volumes of chilled absolute ethanol, incubated at −20 °C for 1 h and centrifuged at 3500× *g* for 20 min at 4 °C (KUBOTA, Osaka, Japan). The pellet containing exopolysaccharides was dissolved in sterile water and measured by the phenol-sulfuric acid method. Fifty microliters of re-suspended sample was mixed with 200 μL phenol, and then, 750 μL sulfuric acid was added. The solution was left standing for 40 min, and vigorously shaken. After shaking, the A~490nm~ was measured using a spectrophotometer (U3310, HITACHI, Tokyo, Japan), and the amount of total sugar (excluding amino sugars) was calculated with a standard curve established using glucose.

5.5. Binding Activity of rHPL~OE~ to Biofilm or Di-Rhamnolipid {#sec5dot5-marinedrugs-17-00355}
--------------------------------------------------------------

Di-rhamnolipid (95%, \#R95DD), phosphate buffer saline (PBS, \#P3813), Tween-20 (\#P1379), [l]{.smallcaps}-rhamnose (≥99%, \#R3875), [d]{.smallcaps}-glucose (≥99.5%, \#G8270), [d]{.smallcaps}-galactose (≥99%, \#G0750), [d]{.smallcaps}-fructose (≥99%, \#F0127), [d]{.smallcaps}-mannose (≥99%, \#M8574) and sodium alginate (\#W201502) was purchased from Sigma-Aldrich (St. Louis, MO, USA). For competitive enzyme-linked immunosorbent assays (ELISA), the extracted biofilm or prepared di-rhamnolipid solution (120 μg/mL in ddH~2~O) was diluted in 10× the volume of the coating solution (\#5150−0014, SeraCare KPL, Milford, MA, USA), and 50 μL of the mixture was added to each well of the 96-well microplate (\#442404, Thermo Fisher, Waltham, MA, USA) and incubated at 4 °C overnight. After blocking with a blocking reagent (\#10057177103, Roche, Basel, Switzerland) at 37 °C for 1 h, the plates were washed with PBST (PBS with 0.05% Tween-20) three times. To the washed wells, 25 μL of 0.2 μM rHPL~OE~ was mixed with 25 μL of two-fold the indicated concentration of [l]{.smallcaps}-rhamnose, [d]{.smallcaps}-glucose, [d]{.smallcaps}-galactose, [d]{.smallcaps}-fructose, [d]{.smallcaps}-mannose or sodium alginate and the mixture was added to the wells, which were maintained at 37 °C for 1 h. Fifty microliters of 0.1 μM purified rHPL~OE~ was added in parallel as a positive control, and Tris-buffer (20 mM Tris-HCl and 200 mM NaCl, pH 7.4) was added in parallel as a negative control. After washing three times with PBST, the microplates were incubated with monoclonal anti-His-tag (1:5000; \#631212, Clontech, Mountain View, CA, USA) in PBST at 37 °C for 1 h. Subsequently, horseradish peroxidase-conjugated anti-mouse IgG (1:5000; \#AB2338512, Jackson ImmunoResearch, West Grove, PA, USA) in PBST was added to the microplates, and after washing three times with PBST, the plates were incubated at 37 °C for 1 h. After being washed three times with PBST, 100 μL of 3,3',5,5'-tetramethylbenzidine substrate (\#5120-0077, SeraCare KPL, Milford, MA, USA) was added to each well and incubated at 37 °C for exactly 15 min. Finally, the reaction was terminated by the addition of 100 μL of 2 N H~2~SO~4~. The A~450nm~ was read using a microplate spectrophotometer (iMark Microplate Absorbance Reader, Bio-Rad, Hercules, CA, USA). The inhibitory constant (*K~i~*) was analyzed with GraphPad 5.0 software (GraphPad Software, La Jolla, CA, USA; fitted with a Binding-Competitive/Onesite-Fit *Ki*).

5.6. Anti-Biofilm Assay {#sec5dot6-marinedrugs-17-00355}
-----------------------

KH~2~PO~4~ (≥99%, \#P5655), K~2~HPO~4~ (≥99%, \#P3768), (NH~4~)~2~SO~4~ (≥99%, \#A4418), MgSO~4~ (≥99.5%, \#M7506), L-arginine (≥98%, \#A5006), polymyxin B (meets USP testing specifications, \#P0972) and crystal violet (≥90%, \#C0775) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Biofilm formation was described by O'Toole \[[@B57-marinedrugs-17-00355]\]. Briefly, overnight culture of the *P. aeruginosa* PA14 in LB medium was diluted with fresh M63 medium (22 mM KH~2~PO~4~, 40 mM K~2~HPO~4~, 15 mM (NH~4~)~2~SO~4~, 1 mM MgSO~4~ and 0.4% [l]{.smallcaps}-arginine). A total of 1 × 10^6^ CFU/well bacterial cells were then cultured with various concentrations of rHPL~OE~ in a final volume of 100 µL M63 medium onto a 96-well clear round bottom polystyrene microplate (\#3788, Thermo Fisher, Waltham, MA, USA) and incubated at 37 °C for 24 h without shaking. A standard antibiotic polymyxin B (50 µg/mL) often used to kill *P. aeruginosa* in other studies was applied as a positive control, and M63 only was used as a negative control. The suspended culture was then discarded, and the plate was washed with ddH~2~O twice to remove any remaining suspended cells in the microtiter wells. The biofilm was then stained with 125 µL of 0.1% crystal violet for 15 min, after which the stained biofilm was washed with ddH~2~O five times to remove any unbound dye. The crystal violet bound to the biofilm was solubilized with 125 µL 30% (*v*/*v*) acetic acid and quantified by measuring the A~595nm~ using the microplate spectrophotometer (iMark Microplate Absorbance Reader, Bio-Rad, Hercules, CA, USA). For the biofilm dispersion test, biofilm cultures were grown statically in 80 µL of M63 medium for 24 h, followed by the addition of 20 µL of the indicated concentration of rHPL~OE~ in M63 medium and incubation for an additional 24 h. The addition of polymyxin B (50 µg/mL) to the culture before biofilm formation was used as a positive control.

5.7. Swarming Motility Measurement {#sec5dot7-marinedrugs-17-00355}
----------------------------------

The swarming motility of *P. aeruginosa* PA14 was investigated in plates containing swarming motility media (LB with 0.5% (wt) glucose and 0.6% (wt) agar). Agar was purchased from OXOID (\#LP0011, Basingstoke, Hampshire, UK). An aliquot of 2 μL of motility media containing 1 × 10^6^ CFU/mL bacterial cells was inoculated in plates with different concentrations of rHPL~OE~. Subsequently, spots were dired for 20 min at room temperature and incubated at 37 °C for 48 h. The diameter of the circular bacterial growth was measured \[[@B50-marinedrugs-17-00355]\].

5.8. Extracellular Rhamnolipid Quantification {#sec5dot8-marinedrugs-17-00355}
---------------------------------------------

Methylene blue (≥82%, \#M9140), sodium borate (ACS reagent, ≥99.5%, \#S9640) and chloroform (≥99.5%, \#C2432) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Rhamnolipid was quantified as described by Pinzon et al. \[[@B58-marinedrugs-17-00355]\]. The supernatant of the anti-biofilm test was collected, and bacterial cells were removed by centrifugation (KUBOTA, Osaka, Japan). The pH of the cell-free supernatant was first adjusted to 2.3 ± 0.2 using 1 N HCl. Two hundred microliters of acidified sample was then extracted with the same volume of chloroform five times. One milliliter of the chloroform extract was carefully removed and mixed with 40 μL of 0.1% methylene blue (freshly prepared and pH adjusted to 8.6 ± 0.2 with 50 mM borate buffer) and 960 μL of distilled water in a 2 mL tube. After being vigorously shaken for 4 min, the samples were left to stand for 15 min. The chloroform phase was transferred into a quartz cuvette and value of A~638\ nm~ was measured by spectrophotometer (U3310, HITACHI, Tokyo, Japan). The values were converted to rhamnolipid concentrations using a calibration curve established by applying the same procedure to standard rhamnolipid solutions of different concentrations.

5.9. Azocasein Degradation Assay {#sec5dot9-marinedrugs-17-00355}
--------------------------------

The proteolytic activity was determined in the cell-free culture supernatant according to the method by Kessler et al. \[[@B59-marinedrugs-17-00355]\]. The amount of protease released by *P. aeruginosa* treated by rHPL~OE~, the supernatant of the anti-biofilm test was collected by centrifugation (KUBOTA, Osaka, Japan). One hundred and fifty microliters of supernatant were added to 0.3% of 1 mL azocasein (\#A2765, Sigma-Aldrich St. Louis, MO, USA) in 50 mM Tris-HCl (pH 7.5) and incubated at 37 °C for 15 min. The reaction was stopped by the addition of 0.5 mL 10% trichloroacetic acid, and the mixture was centrifuged at 8000× *g* for 5 min (KUBOTA, Osaka, Japan) to obtain a clear supernatant. The absorbance of the clear supernatant was then measured at 400 nm (U3310, HITACHI, Tokyo, Japan) \[[@B60-marinedrugs-17-00355]\].

5.10. Pyoverdine Quantification Assay {#sec5dot10-marinedrugs-17-00355}
-------------------------------------

*P. aeruginosa* was incubated with different concentrations of rHPL~OE~ at 37 °C for 24 h. Thereafter, the cultured liquid was centrifuged at 8000× *g* for 15 min (KUBOTA, Osaka, Japan), and the cell-free supernatant was used for the pyoverdine measurement. The relative concentrations of pyoverdine in all of the treated supernatants with respect to the control was measured through a fluorescence microplate spectrophotometer (Victor2, PerkinElmer, Waltham, MA, USA) at an excitation wavelength of 405 nm and an emission wavelength of 465 nm \[[@B61-marinedrugs-17-00355]\].

5.11. Pyocyanin Quantification Assay {#sec5dot11-marinedrugs-17-00355}
------------------------------------

The pyocyanin quantification assay was performed according to the method described by Essar et al. \[[@B62-marinedrugs-17-00355]\]. *P. aeruginosa* was incubated with different concentrations of rHPL~OE~ at 37 °C for 24 h, and the cell-free supernatant was collected by centrifugation (KUBOTA, Osaka, Japan). Five milliliters of the supernatant were extracted with 3 mL of chloroform and the chloroform layer was re-extracted with 1 mL of 0.2 N HCl to produce an orange yellow to pink solution, and the chloroform phase was transferred into a quartz cuvette and value of A~520\ nm~ was measured by a spectrophotometer (U3310, HITACHI, Tokyo, Japan).

5.12. Synergistic Effect of rHPL~OE~ with Antibiotics {#sec5dot12-marinedrugs-17-00355}
-----------------------------------------------------

The experiment design was according to the method described by Das et al. \[[@B63-marinedrugs-17-00355]\]. *P. aeruginosa* with a mature biofilm was treated with rHPL~OE~ in combination with either azithromycin (≥95%, \#75199, Sigma-Aldrich, St. Louis, MO, USA) \[[@B63-marinedrugs-17-00355]\] or cephalexin (≥95%, \#C4895, Sigma-Aldrich, St. Louis, MO, USA) \[[@B64-marinedrugs-17-00355]\]. Solutions of rHPL~OE~ in 0.3125 µM, 0.625 µM, 1.25 µM and 2.5 µM in combination with different concentrations of antibiotics were directly added to the cultured bacterial liquid with a mature biofilm and held at 37 °C for 24 h. The total protein and amount of biofilm were measured to validate the synergistic antibacterial effect of rHPL~OE~ and antibiotics.

5.13. Total Protein Concentration Measurement in the Biofilm {#sec5dot13-marinedrugs-17-00355}
------------------------------------------------------------

Concentration of the extractable protein was determined as a measure of the *P. aeruginosa* biofilm population density. The microbial population density in the biofilm is assumed to be directly proportional to the extractable protein concentration \[[@B56-marinedrugs-17-00355]\]. After incubation, planktonic *P. aeruginosa* cells were removed, and adhered cells remained in the biofilm were gently washed with sterile PBS and boiled for 30 min in 5 mL of 0.5 N NaOH (ACS reagent, ≥97%, \#221465, Sigma-Aldrich, St. Louis, MO, USA) to extract the protein. After that, the suspension was centrifuged at 8000× *g* for 5 min (KUBOTA, Osaka, Japan), and the resulting clear supernatant was collected. The supernatant protein concentration was then measured by the bicinchoninic acid (BCA) protein assay kit (\#23225, Thermo Fisher, Waltham, MA, USA).

5.14. Anti-A549 Infection Assay {#sec5dot14-marinedrugs-17-00355}
-------------------------------

The Roswell Park Memorial Institute (RPMI)-1640 medium (\#10-040 CMS) and Antibiotics--Antimycotic solution (PSA, \#30-004-CIS) was purchased from Corning (Corning, NY, USA). Characterized fetal bovine serum (FBS, \#SH30071) was purchased from HyClone Laboratory (Logan, UT, USA). The A549 infection model was modified from method described by Chi \[[@B65-marinedrugs-17-00355]\]. A549 cells (ATCC^®^ number: CCL-185™, BCRC, Hsinchu, Taiwan), adenocarcinomic human lung cells, were seeded in 96-well tissue culture plates at 2 × 10^4^ containing 100 µL of RPMI-1640 medium supplemented with 10% (*v*/*v*) fetal FBS and 1% (*v*/*v*) PSA and allowed to grow at 37 °C for 16 to 18 h. Culture supernatants were removed, the monolayer was washed once with PBS buffer, and then 50 µL of serum-free RPMI-1640 containing two times the indicated concentration of rHPL~OE~ was added to cells and incubated for 30 min, followed by inoculation with *P. aeruginosa* PA14. RPMI-1640 with 5 µM BSA or rHPL~DM~ was used as negative controls. For inoculation, the fresh bacterial cells cultured in LB broth were washed with PBS, re-suspended and diluted in RPMI-1640 medium to a concentration of 1 × 10^8^ CFU/mL. Thereafter, 50 µL of the bacterial dilution was applied to the rHPL~OE~-treated A549 cells at a multiplicity of infection (MOI) of 50 (i.e., 1 × 10^6^ CFU/50 µL/well). The blank group was A549 cells treated by 2.5 μM rHPL~OE~ without bacterial infection. After infection for 16 h at 37 °C, the A549 cell viability was determined by the AlamarBlue cell viability assay (BUF012B, Bio-Rad, Hercules, CA, USA). It should be noted that 50 µg/mL polymyxin B should be added to alamarBlue reagent to prevent a survival signal from residual bacteria. The level of viability, expressed as a percentage, was calculated as follows: % viability = \[OD of assay cells/OD of control cells\] × 100.

5.15. Anti-Zebrafish Infection Assay {#sec5dot15-marinedrugs-17-00355}
------------------------------------

Zebrafish embryos were purchased from Gendanio Biotech Inc. (New Taipei City, Taiwan). Healthy, transparent and regular embryos were selected and aliquoted into 96-well plates with four embryos per well, followed by incubation at 28 °C in 100 µL embryo water. Thereafter, 100 µL of *P. aeruginosa* (1 × 10^8^ CFU/mL) pre-incubated with 5 mM rHPL~OE~ for 1 h was added to the embryos at 24 h post-fertilization (hpf). The zebrafish embryos were further incubated at 28 °C, and the development of each embryo in 24 h and 48 h was observed using an inverted microscope (TS100, NIKON, Tokyo, Japan) equipped with a digital camera. The number of larva at 48 h in each group was counted, and the rate of successful development was calculated. All zebrafish related experiments were conducted in accordance with the ethical guidelines of Council of Agriculture, Executive Yuan and Ministry of Science and Technology.

5.16. Statistical Analyses {#sec5dot16-marinedrugs-17-00355}
--------------------------

All statistical analyses were carried out using GraphPad Prism version 5.01 for Windows (GraphPad Software, La Jolla, CA, USA). Each value was the average of three measurements, where the presented data is the mean ± SD. All means were compared by one-way ANOVA.

We thank Hwan-You Chang for providing *P. aeruginosa* PA14. We also thank Yung-Jen Chuang for directing the experiments about zebrafish, as well as for providing valuable comments.

The following are available online at <https://www.mdpi.com/1660-3397/17/6/355/s1>. The supplementary materials contained: 1. Table S1 FPLC purification scheme of rHPL~OE~, 2. Figure S1. Bacterial cell or PAMP binding activity of rHPL~OE~ and rHPL~DM~, 3. Figure S2. Purification and characterization of rHPL~OE~ with HisTrap™ HP immobilized metal ion affinity chromatography, 4. Figure S3. Secondary structure analysis of rHPL~OE~, rHPL~DM~ and rHPL using circular dichroism (CD), 5. Figure S4. Structure and NMR spectra (^1^H and ^13^C) of pehnylthio-1-2-rhamnobioside, 6. Figure S5. Structure and NMR spectra (^1^H and ^13^C) of phenylthio-1-3-rhamnobioside, 7. Figure S6. Structure and NMR spectra (^1^H and ^13^C) of Psl-pentasaccharide. 4-Methoxyphenyl α-[d]{.smallcaps}-mannopyranosyl-(1→2)-β-[d]{.smallcaps}-mannopyranosyl-(1→3)-β-[d]{.smallcaps}-mannopyranosyl-(1→3)-α-[l]{.smallcaps}-rhamnopyranosyl-(1→3)-β-[d]{.smallcaps}-glucopyranoside, 8. Figure S7. Inhibitory effect on the swarming motility of *P. aeruginosa* PA14 by rHPL~OE~ or rHPL~DM~, 9. Figure S8. Down-regulation effect on the extracellular protease activities or QS-factors of *P. aeruginosa* PA14 by rHPL~OE~.
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![Inhibitory effects of monosaccharides on the recombinant hemolymph plasma lectin (rHPL~OE~)-biofilm interaction. The binding activity of rHPL~OE~ to the PA14 biofilm and inhibitory effects of monosaccharides or alginate on this binding were determined by competitive ELISA. rHPL~DM~ was applied as a negative control. \*\*\* *p* \< 0.001 versus the rHPL~OE~ only group (positive control).](marinedrugs-17-00355-g001){#marinedrugs-17-00355-f001}

![Structures of synthesized rhamnobioses and the rhamnose-containing Psl-pentasaccharide and inhibitory effects of thereof on the rHPL~OE~-biofilm interaction. (**A**) Structures of the synthesized rhamnosyl di- and pentasaccharides: α(1-2)-rhamnobiose, α(1-3)-rhamnobiose, phenylthio-1-2-rhamnobioside, phenylthio-1-3-rhamnobioside, propargyl-1-3-rhamnobioside and Psl-pentasaccharide. (**B**) The binding activity of rHPL~OE~ on the biofilm from *Pseudomonas aeruginosa* PA14 and the inhibitory effects of rhamnose or rhamnobiosides on this binding were determined by competitive ELISA. \*\*\* *p* \< 0.001 versus the rHPL~OE~-only group.](marinedrugs-17-00355-g002){#marinedrugs-17-00355-f002}

![Inhibitory effects of monosaccharides on the rHPL~OE~-di-rhamnolipid interaction. The binding activity of rHPL~OE~ for di-rhamnolipid and inhibitory effects of monosaccharides on this binding was determined by competitive ELISA (competed with by [l]{.smallcaps}-rhamnose, [d]{.smallcaps}-glucose, [d]{.smallcaps}-galactose, [d]{.smallcaps}-mannose and [d]{.smallcaps}-fructose). \*\*\* *p* \< 0.001 versus the rHPL~OE~-only group.](marinedrugs-17-00355-g003){#marinedrugs-17-00355-f003}

![Inhibitory and dispersion effect on the biofilm of *P. aeruginosa* PA14 by rHPL~OE~. Quantification of crystal violet staining associated with (**A**) the biofilm of *P. aeruginosa* PA14 after treatment with rHPL~OE~ at the indicated concentration for 24 h and (**B**) after biofilm formation for 24 h and treatment with rHPL~OE~ at the indicated concentration for a further 24 h. rHPL~DM~ was applied as a negative control. The buffer-treated group was set as 100% (mock). \* *p* \< 0.05 and \*\*\* *p* \< 0.001 versus the buffer-treated group.](marinedrugs-17-00355-g004){#marinedrugs-17-00355-f004}

![Down-regulation effect on extracellular rhamnolipids of *P. aeruginosa* PA14 by rHPL~OE~ or rHPL~DM~. Extracellular rhamnolipids of *P. aeruginosa* PA14 treated by rHPL~OE~ or rHPL~DM~ were measured by the chloroform--methyl blue method. \*\*\* *p* \< 0.001 versus the buffer-treated group.](marinedrugs-17-00355-g005){#marinedrugs-17-00355-f005}

![Synergistic effect of rHPL~OE~ with IC50 doses of azithromycin and cephalexin on *P. aeruginosa*. Quantity of the percentage of biofilm total protein inhibition (with respect to the antibiotic-only control) of *P. aeruginosa* PA14. \*\*\* *p* \< 0.001 versus the control group.](marinedrugs-17-00355-g006){#marinedrugs-17-00355-f006}

![Inhibitory activities of rHPL~OE~ on *P. aeruginosa* PA14 infection of human A549 lung cells. The percent cell death was quantified by the alamarBlue cell viability assay and normalized to cells in the absence of rHPL~OE~, for which the cell death was set as 100%. \*\*\* *p* \< 0.001 versus the control group.](marinedrugs-17-00355-g007){#marinedrugs-17-00355-f007}

![Inhibitory activity of rHPL~OE~ on *P. aeruginosa* PA14 infection of zebrafish embryos. Zebrafish embryos were infected with *P. aeruginosa* PA14 in the presence or absence of rHPL~OE~ and imaged after 48 h of infection. All of the pictures were taken with an inverted microscope at 40×.](marinedrugs-17-00355-g008){#marinedrugs-17-00355-f008}
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Inhibition percentage (%) of QS-factors in rHPL~OE~ treated *P. aeruginosa* PA14.

                                          rHPL~OE~(μM)   0.31        0.63         1.25
  --------------------------------------- -------------- ----------- ------------ -------------
  Activities of extracellular proteases   7 ± 1.4        4.8 ± 0.8   15.9 ± 2.2   12.4 ± 1.4
  Pyoverdine                              12.3 ± 0.2     8.2 ± 0.2   16.7 ± 0.2   21.2 ± 0.2
  Pyocyanin                               40.8 ± 13.9    56.1 ± 4    45.4 ± 9.2   40.5 ± 24.2
